Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats

Neuropharmacology

Volumn 57, Issue 7-8, 2009, Pages 665-672

  Seu, Emanuele ^a   David Jentsch, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; Inhibitory control; Methylphenidate; Norepinephrine reuptake inhibitors; Prefrontal cortex; Reversal learning

Indexed keywords

DESIPRAMINE; METHYLPHENIDATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; LEARNING; MALE; MENTAL TASK; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; RETREATMENT; TASK PERFORMANCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIPRAMINE; DISCRIMINATION LEARNING; MALE; METHYLPHENIDATE; RATS; RATS, LONG-EVANS; REACTION TIME; REVERSAL LEARNING; SERIAL LEARNING; TIME FACTORS;

EID: 70350225690     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.08.007     Document Type: Article

References (53)

1. Arnsten A.F. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31 (2006) 2376-2383
2. Aron A.R., Dowson J.H., Sahakian B.J., and Robbins T.W. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 54 (2003) 1465-1468
3. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., Hamilton C., and Spencer R.C. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 60 (2006) 1111-1120
4. Boulougouris V., Dalley J.W., and Robbins T.W. Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behav. Brain Res. 179 (2007) 219-228
5. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
6. Carboni E., Silvagni A., Vacca C., and Di Chiara G. Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J. Neurochem. 96 (2006) 473-481
7. Chamberlain S.R., Del Campo N., Dowson J., Muller U., Clark L., Robbins T.W., and Sahakian B.J. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol. Psychiatry (2007)
8. Chamberlain S.R., Muller U., Blackwell A.D., Clark L., Robbins T.W., and Sahakian B.J. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311 (2006) 861-863
9. Clatworthy P.L., Lewis S.J., Brichard L., Hong Y.T., Izquierdo D., Clark L., Cools R., Aigbirhio F.I., Baron J.C., Fryer T.D., and Robbins T.W. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J. Neurosci. 29 (2009) 4690-4696
10. Dias R., Robbins T.W., and Roberts A.C. Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380 (1996) 69-72
11. Eagle D.M., Tufft M.R., Goodchild H.L., and Robbins T.W. Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl) 192 (2007) 193-206
12. Faraone S.V., Biederman J., Spencer T., Michelson D., Adler L., Reimherr F., and Glatt S.J. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav. Brain Funct. 1 (2005) 16
13. Faraone S.V., Biederman J., Spencer T., Michelson D., Adler L., Reimherr F., and Seidman L. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 15 (2005) 664-670
14. Frank M.J., Santamaria A., O'Reilly R.C., and Willcutt E. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology 32 (2007) 1583-1599
15. Garcia A.S., Barrera G., Burke T.F., Ma S., Hensler J.G., and Morilak D.A. Autoreceptor-mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment. J. Neurochem. 91 (2004) 683-693
16. Hesslinger B., Tebartz van Elst L., Thiel T., Haegele K., Hennig J., and Ebert D. Frontoorbital volume reductions in adult patients with attention deficit hyperactivity disorder. Neurosci. Lett. 328 (2002) 319-321
17. Itami S., and Uno H. Orbitofrontal cortex dysfunction in attention-deficit hyperactivity disorder revealed by reversal and extinction tasks. Neuroreport 13 (2002) 2453-2457
18. Izenwasser S., Coy A.E., Ladenheim B., Loeloff R.J., Cadet J.L., and French D. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur. J. Pharmacol. 373 (1999) 187-193
19. Jentsch J.D. Genetic vasopressin deficiency facilitates performance of a lateralized reaction-time task: altered attention and motor processes. J. Neurosci. 23 (2003) 1066-1071
20. Jentsch J.D., Aarde S.M., and Seu E. Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology (Berl) 202 (2009) 497-504
21. Kempton S., Vance A., Maruff P., Luk E., Costin J., and Pantelis C. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol. Med. 29 (1999) 527-538
22. Kozisek M.E., Deupree J.D., Burke W.J., and Bylund D.B. Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies. J. Neurosci. Methods 163 (2007) 83-91
23. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68 (1997) 2032-2037
24. Lapiz M.D., Bondi C.O., and Morilak D.A. Chronic treatment with desipramine improves cognitive performance of rats in an attentional set-shifting test. Neuropsychopharmacology 32 (2007) 1000-1010
25. Maidment I.D. The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J. Psychopharmacol. 17 (2003) 332-336
26. Makris N., Biederman J., Valera E.M., Bush G., Kaiser J., Kennedy D.N., Caviness V.S., Faraone S.V., and Seidman L.J. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb. Cortex 17 (2007) 1364-1375
27. Mazei M.S., Pluto C.P., Kirkbride B., and Pehek E.A. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res. 936 (2002) 58-67
28. Mehta M.A., Calloway P., and Sahakian B.J. Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder. J. Psychopharmacol. 14 (2000) 299-302
29. Mehta M.A., Goodyer I.M., and Sahakian B.J. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J. Child. Psychol. Psychiatry 45 (2004) 293-305
30. Mehta M.A., Owen A.M., Sahakian B.J., Mavaddat N., Pickard J.D., and Robbins T.W. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 20 (2000) RC65
31. Moron J.A., Brockington A., Wise R.A., Rocha B.A., and Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22 (2002) 389-395
32. Navarra R., Graf R., Huang Y., Logue S., Comery T., Hughes Z., and Day M. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 34-41
33. Rhodes S.M., Coghill D.R., and Matthews K. Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. Psychopharmacology (Berl) 175 (2004) 319-330
34. Rhodes S.M., Coghill D.R., and Matthews K. Acute neuropsychological effects of methylphenidate in stimulant drug-naive boys with ADHD II - broader executive and non-executive domains. J. Child. Psychol. Psychiatry 47 (2006) 1184-1194
35. Robinson E.S., Eagle D.M., Mar A.C., Bari A., Banerjee G., Jiang X., Dalley J.W., and Robbins T.W. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology (2007)
36. Schachar R., Mota V.L., Logan G.D., Tannock R., and Klim P. Confirmation of an inhibitory control deficit in attention-deficit/hyperactivity disorder. J. Abnorm. Child. Psychol. 28 (2000) 227-235
37. Schachar R., Tannock R., Marriott M., and Logan G. Deficient inhibitory control in attention deficit hyperactivity disorder. J. Abnorm. Child. Psychol. 23 (1995) 411-437
38. Scheres A., Oosterlaan J., Swanson J., Morein-Zamir S., Meiran N., Schut H., Vlasveld L., and Sergeant J.A. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. J. Abnorm. Child. Psychol. 31 (2003) 105-120
39. Seu E., and Jentsch J.D. Alpha-2 noradrenergic mechanisms modulate the acquisition and reversal of a position discrimination task in rats. Soc. Neurosci. (2006) Abstr., 571.517
40. Seu E., Lang A., Rivera R.J., and Jentsch J.D. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. Psychopharmacology (Berl) 202 (2009) 505-519
41. Spencer T., Biederman J., Coffey B., Geller D., Crawford M., Bearman S.K., Tarazi R., and Faraone S.V. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 59 (2002) 649-656
42. Spencer T., Biederman J., Heiligenstein J., Wilens T., Faries D., Prince J., Faraone S.V., Rea J., Witcher J., and Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 11 (2001) 251-265
43. Spencer T., Biederman J., Wilens T., Doyle R., Surman C., Prince J., Mick E., Aleardi M., Herzig K., and Faraone S. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 456-463
44. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., Harding M., Faraone S.V., and Seidman L. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 155 (1998) 693-695
45. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., and Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50 (2006) 755-760
46. Tannock R., Ickowicz A., and Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J. Am. Acad. Child. Adolesc. Psychiatry 34 (1995) 886-896
47. Tannock R., Schachar R., and Logan G. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J. Abnorm. Child. Psychol. 23 (1995) 235-266
48. Tannock R., Schachar R.J., Carr R.P., Chajczyk D., and Logan G.D. Effects of methylphenidate on inhibitory control in hyperactive children. J. Abnorm. Child. Psychol. 17 (1989) 473-491
49. Thanos P.K., Michaelides M., Benveniste H., Wang G.J., and Volkow N.D. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol. Biochem. Behav. 87 (2007) 426-433
50. Valera E.M., Faraone S.V., Murray K.E., and Seidman L.J. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry 61 (2007) 1361-1369
51. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 11 (2001) 25-34
52. Wernicke J.F., Adler L., Spencer T., West S.A., Allen A.J., Heiligenstein J., Milton D., Ruff D., Brown W.J., Kelsey D., and Michelson D. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J. Clin. Psychopharmacol. 24 (2004) 30-35
53. Zhao Z., Baros A.M., Zhang H.T., Lapiz M.D., Bondi C.O., Morilak D.A., and O'Donnell J.M. Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Neuropsychopharmacology 33 (2008) 3190-3200